Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Lau, Amy Y T
Ng, Angel S N
Ng, Patrick K S
Arold, Stefan T.
Cheung, Lydia W T
KAUST DepartmentBioscience Program
Biological and Environmental Science and Engineering (BESE) Division
Computational Bioscience Research Center (CBRC)
Permanent link to this recordhttp://hdl.handle.net/10754/671188
MetadataShow full item record
AbstractThe phosphoinositide 3-kinase regulatory subunit p85α is a key regulator of kinase signaling and is frequently mutated in cancers. In the present study, we showed that in addition to weakening the inhibitory interaction between p85α and p110α, a group of driver mutations in the p85α N-terminal SH2 domain activated EGFR, HER2, HER3, c-Met, and IGF-1R in a p110α-independent manner. Cancer cells expressing these mutations exhibited the activation of p110α and the AKT pathway. Interestingly, the activation of EGFR, HER2, and c-Met was attributed to the ability of driver mutations to inhibit HER3 ubiquitination and degradation. The resulting increase in HER3 protein levels promoted its heterodimerization with EGFR, HER2, and c-Met, as well as the allosteric activation of these dimerized partners; however, HER3 silencing abolished this transactivation. Accordingly, inhibitors of either AKT or the HER family reduced the oncogenicity of driver mutations. The combination of these inhibitors resulted in marked synergy. Taken together, our findings provide mechanistic insights and suggest therapeutic strategies targeting a class of recurrent p85α mutations.
CitationLi, X., Lau, A. Y. T., Ng, A. S. N., Aldehaiman, A., Zhou, Y., Ng, P. K. S., … Cheung, L. W. T. (2021). Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases. Proceedings of the National Academy of Sciences, 118(37), e2101751118. doi:10.1073/pnas.2101751118
SponsorsThis study was supported by the National Natural Science Foundation of China (Grants 81703066 and 82022078 to L.W.T.C.). S.T.A. and A.A. were supported by King Abdullah University of Science and Technology (KAUST) through the baseline fund and Awards FCC/1/1976-25 and REI/1/4446-01 from the Office of Sponsored Research. We thank I. Salem, R. Ramakrishnan, and S. Hong for their comments on the manuscript, as well as Huma Khurram and the KAUST Bioscience Core Lab for assistance with the mass spectrometry.
Except where otherwise noted, this item's license is described as This open access article is distributed under Creative Commons Attribution-NonCommercialNoDerivatives License 4.0 (CC BY-NC-ND).
- Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
- Authors: Hon WC, Berndt A, Williams RL
- Issue date: 2012 Aug 9
- Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
- Authors: Hofmann BT, Jücker M
- Issue date: 2012 Oct
- Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.
- Authors: Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn CR
- Issue date: 2000 Nov
- Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
- Authors: Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK
- Issue date: 2010 Aug 31
- PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
- Authors: Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW
- Issue date: 2011 Jun 15